Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-21), Spyre Therapeutics's 3-1 Month Momentum % is 15.69%.
The industry rank for Spyre Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
FRA:3920's 3-1 Month Momentum % is ranked better than 81.48% of 1382
companies
in the Biotechnology industry
Industry Median: 0.36
vs FRA:3920: 15.69
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Spyre Therapeutics 3-1 Month Momentum % Related Terms
FRA:3920 vs TGTX, IMVT, IBRX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Spyre Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spyre Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Spyre Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spyre Therapeutics (FRA:3920) has a 3-1 Month Momentum % of 15.69% as of Sep. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Spyre Therapeutics and its competitors. According to the industry distribution chart, Spyre Therapeutics ranks #256 out of 1382 companies in the Biotechnology industry, placing it in the top 18.5%.
Is Spyre Therapeutics' 3-1 Month Momentum % too high?
Spyre Therapeutics' current 3-1 Month Momentum % is 15.69%. The Biotechnology industry median 3-1 Month Momentum % is 0.36. Spyre Therapeutics' value of 15.69% is 4258.3% above this industry median. Based on the distribution chart, Spyre Therapeutics ranks #256 out of 1382 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spyre Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' 3-1 Month Momentum % compare to TGTX and IMVT?
According to the Biotechnology industry distribution chart, Spyre Therapeutics ranks #256 out of 1382 companies for 3-1 Month Momentum %. This places Spyre Therapeutics in the top 19% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.36. Spyre Therapeutics' value of 15.69% is 4258.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 0.36, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spyre Therapeutics's current 3-1 Month Momentum % of 15.69% is 4258.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Spyre Therapeutics and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 0.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spyre Therapeutics's current 3-1 Month Momentum % is 15.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spyre Therapeutics (FRA:3920) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.98, compared to a current price of €79.50 — trading 3915.2% above its estimated fair value. The current 3-1 Month Momentum % is 15.69% and 4258.3% above the Biotechnology industry median of 0.36. Spyre Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current 3-1 Month Momentum % is 15.69% as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spyre Therapeutics (FRA:3920) Overvalued in 2026?
Based on GuruFocus' analysis, Spyre Therapeutics stock appears to be overvalued.
The current stock price of €79.50 is trading 3915.2% above its estimated GF Value™ of €1.98.
GuruFocus considers Spyre Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:3920:
3-1 Month Momentum %: 15.69%
GF Value™: €1.98 vs. price of €79.50 (3915.2% above fair value)
Industry Position: 4258.3% above the Biotechnology median (#256 of 1382)
No single metric tells the full story. See the FRA:3920 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
29GF Score
Get the complete analysis for FRA:3920
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3920 has been successfully added to your 
